Pipeline Update from XenoPort - Analyst Blog
January 16 2014 - 6:50PM
Zacks
Pipeline updates are highly awaited events in the pharma/biotech
sector as they play an important role in deciding whether or not to
invest in a particular company. These updates provide information
on experimental drugs and at times give an insight into the
commercial potential of the candidate once it is successfully
developed and commercialized.
With the commencement of 2014, several companies have been
providing an update on their pipelines candidates and their future
developmental plans. Earlier this week, XenoPort,
Inc. (XNPT) provided an update on its pipeline including
the U.S. Food and Drug Administration’s (FDA) feedback on XP23289
and its commercialization plans for Horizant.
XP23289 is being developed for the treatment of relapsing forms of
multiple sclerosis (MS). XenoPort received a feedback from the FDA
on XP23289. The FDA said that XenoPort should explore different
doses of XP23829 to evaluate the potential advantages of doses that
produced either higher or lower monomethyl fumarate (MMF) exposure.
XenoPort intends to continue discussions with the agency regarding
the regulatory pathway for the candidate.
Meanwhile, XenoPort will also file an Investigational New Drug
(IND) application for XP23829 for the treatment of
moderate-to-severe plaque psoriasis. A phase II study for this
indication could commence by mid 2014.
As far as the performance of Horizant is concerned, since XenoPort
started promoting the drug (Jun 2013), the company said that it
expects the Horizant to break-even and turn profitable by the end
of 2015.
With Horizant being a lead product in XenoPort’s portfolio, results
from the post-marketing study on the drug will be game changing for
the company. We expect investor focus to remain on Horizant
updates.
XenoPort carries a Zacks Rank #3 (Hold). Some better ranked stocks
in the same sector include Actelion Ltd. (ALIOF),
Coronado Biosciences, Inc. (CNDO) and
Acceleron Pharma, Inc. (XLRN). While Actelion and
Coronado Biosciences are Zacks Rank #1 (Strong Buy) stocks,
Acceleron is a Zacks Rank #2 (Buy) stock.
ACTELION LTD (ALIOF): Get Free Report
CORONADO BIOSCI (CNDO): Free Stock Analysis Report
ACCELERON PHARM (XLRN): Free Stock Analysis Report
XENOPORT INC (XNPT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Apr 2024 to May 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From May 2023 to May 2024